Trademark: 90252361
Word
P HLA PROTEIN
Status
Registered
Status Code
700
Status Date
Tuesday, August 23, 2022
Serial Number
90252361
Registration Number
6828530
Registration Date
Tuesday, August 23, 2022
Mark Type
3000
Filing Date
Tuesday, October 13, 2020
Published for Opposition
Tuesday, September 7, 2021

Trademark Owner History
Pure Protein L.L.C. - Original Registrant

Classifications
5 Chemicals and biochemicals for in vitro clinical and medical use
1 Reagents for scientific, pharmaceutical, clinical, and medical research purposes; laboratory chemicals, namely, protein-based reagents used for the detection of antibodies and receptors in cell, blood, and tissue analysis for in vitro diagnostics for scientific use and research in the field of therapeutic reagent designs; chemicals and biochemicals in the nature of reactants and reagents for in vitro scientific or research use; chemicals and biochemicals for use in the manufacture of pharmaceutical preparations; chemical, biochemical and biotechnological solutions and preparations consisting of pre-mixed reactants and reagents for scientific and research use in connection with antibody and B or T cell detection, separation and labelling; biochemical reagents for detecting and analyzing molecules in protein arrays; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; chemical, biochemical and biotechnological products in the nature of reactants and reagents for use in biotechnological product development of therapeutics for the prevention and treatment of cancer, infectious diseases, autoimmune diseases and allergies; chemical, biochemical and biotechnological preparations used in industry and science, and in the development and manufacture of pharmaceuticals, pharmaceutical preparations and substances, for the prevention and treatment of cancer, infectious diseases, autoimmune diseases and allergies; chemical, biochemical and biotechnological preparations used in industry and science, and in the development and manufacture of pharmaceuticals, pharmaceutical preparations and substances, for the detection, prevention and treatment of rejection causing antibodies, B and T cells
44 Medical consulting services for transplant and organ rejection assessment
42 Providing scientific, pharmaceutical, clinical, and medical research information via the internet; research and development of new products; pharmaceutical drug and biomarker preparation target discovery, development, and validation in the nature of research, development, and quality assurance services; pharmaceutical and scientific research and development services; medical research services; medical development services in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology, and clinical trials; clinical research services in the fields of pharmaceuticals, biology, chemistry, biochemistry, and clinical trials; clinical development services in the nature of scientific development of clinical trials; consulting services in the field of pharmaceutical assessment; scientific and medical research consulting services for transplant and organ rejection assessment; validation in the nature of quality assurance services, screening and mapping in the nature of scientific research and development of biological material for drug discovery and vaccine manufacturing purposes; providing scientific information and medical research information in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology, and clinical trials; scientific and medical research and development in the field of cancer, infectious diseases, autoimmune diseases and allergies; scientific and medical research and development in the field of antibody, B cell and T cell detection in transplant and organ rejection
The mark consists of a square on top with two squares on each side touching corners with one square on the bottom with the top left section missing and a floating square in the middle of the four squares forming the letter "P" next to the literal word "HLA Protein".
HUMAN LEUKOCYTE ANTIGEN
"HLA PROTEIN"

Trademark Events
Aug 23, 2022
Notice Of Registration Confirmation Emailed
Aug 23, 2022
Registered-Principal Register
Jul 16, 2022
Notice Of Acceptance Of Statement Of Use E-Mailed
Jul 15, 2022
Allowed Principal Register - Sou Accepted
Jun 23, 2022
Statement Of Use Processing Complete
Jun 3, 2022
Use Amendment Filed
Jun 23, 2022
Case Assigned To Intent To Use Paralegal
Jun 3, 2022
Teas Statement Of Use Received
May 3, 2022
Notice Of Approval Of Extension Request E-Mailed
Apr 29, 2022
Sou Extension 1 Granted
Apr 29, 2022
Sou Extension 1 Filed
Apr 29, 2022
Teas Extension Received
Feb 25, 2022
Assigned To Examiner
Nov 2, 2021
Noa E-Mailed - Sou Required From Applicant
Sep 7, 2021
Official Gazette Publication Confirmation E-Mailed
Sep 7, 2021
Published For Opposition
Aug 18, 2021
Notification Of Notice Of Publication E-Mailed
Aug 1, 2021
Approved For Pub - Principal Register
May 14, 2021
Teas/Email Correspondence Entered
May 14, 2021
Correspondence Received In Law Office
May 14, 2021
Teas Response To Office Action Received
Mar 29, 2021
Notification Of Non-Final Action E-Mailed
Mar 29, 2021
Non-Final Action E-Mailed
Mar 29, 2021
Non-Final Action Written
Mar 11, 2021
Assigned To Examiner
Dec 3, 2020
Notice Of Design Search Code E-Mailed
Dec 2, 2020
New Application Office Supplied Data Entered
Oct 16, 2020
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24